Renin Angiotensin Aldosterone System Archives
Mar. 17, 2022—A Vanderbilt study found that renin-angiotensin-aldosterone system (RAASi) inhibitor drugs, which are commonly used to regulate high blood pressure, do not disproportionately increase the risk of acute kidney injury (AKI) in patients with COVID-19 compared to patients hospitalized with influenza.
May. 6, 2021—The Vanderbilt Institute for Clinical and Translational Research (VICTR) has been awarded a major federal grant to lead a national trial of treatments targeting the Renin Angiotensin Aldosterone System (RAAS) in patients hospitalized with COVID-19.